Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: A non-inferiority randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 8, 2014, Pages 1508-1514

  Mariette, Xavier ^a   Rouanet, Stephanie ^b   Sibilia, Jean ^c   Combe, Bernard ^d   Loët, Xavier Le ^e   Tebib, Jacques ^f   Jourdan, Rosemary ^b   Dougados, Maxime ^g  

^a INSERM   (France)

^b Roche   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d UNIV MONTPELLIER   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g Department of Rheumatology Hôpital Cochin Rene Descartes University ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; IMMUNOGLOBULIN M; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHITIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DAS28; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEPATITIS B; HUMAN; IMMUNOGLOBULIN G DEFICIENCY; INFECTION; INFUSION RELATED REACTION; LOW DRUG DOSE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OPEN STUDY; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VASCULAR DISEASE;

B CELLS; RHEUMATOID ARTHRITIS; TREATMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; RETREATMENT; TREATMENT OUTCOME;

EID: 84903890133     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203480     Document Type: Article

References (20)

1. Markenson JA, Gibofsky A, Palmer WR, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011;38:1273-81.
2. Jönsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008;8 (Suppl 2):S61-86.
3. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
4. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.
5. MabThera SPC. Roche Registration Limited, Welwyn Garden City, UK. 2008. http://www.mabthera-ra.com/fmfiles/re7228001/about-mabthera/MabThera-EU-SmPC- Jan-2012.pdf (accessed 20 Mar 2012).
6. Data on File. Roche, Boulogne Billancourt, France.
7. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
8. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
9. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
10. Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
11. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
12. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44. (Pubitemid 47492478)
13. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology 2010;49:1683-93.
14. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Hensor EMA, Emery P, Bingham SJ, et al. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28 (ESR) and DAS-28 (CRP): can they be reduced? Rheumatology 2010;49:1521-9.
17. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32.
18. Gottenberg J-E, Ravaud P, Bardin T, et al. Low serum IgG level after rituximab is associated with an increased risk of serious infections in rheumatoid arthritis: data of the AIR Registry. Arthritis Rheum 2011;63 (Suppl):S641.
19. van Vollenhoven R, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis:9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72: 1496-502.
20. Gottenberg J-E, Ravaud P, Bardin T, et al. Opportunistic infections in patients with rheumatoid arthritis treated with rituximab: data from the autoimmunity and rituximab registry. Arthritis Rheum 2012;64 (Supp 10):S561.